
EMA recommends extension of approval for tadalafil
The At its meeting in December 2022 a Extension forTadalafil (Adcirca, Eli Lilly) recommended: The indication should be extended to the treatment of pediatric patients 2 years of age and older with pulmonary arterial hypertension, classified as WHO functional classes II and III.Until now, the indication was limited to adult patients. This full text is unfortunately […]